Time-resolved Role of P2X4 and P2X7 During CD8 T Cell Activation
Overview
Authors
Affiliations
CD8 T cells are a crucial part of the adaptive immune system, responsible for combating intracellular pathogens and tumor cells. The initial activation of T cells involves the formation of highly dynamic Ca microdomains. Recently, purinergic signaling was shown to be involved in the formation of the initial Ca microdomains in CD4 T cells. In this study, the role of purinergic cation channels, particularly P2X4 and P2X7, in CD8 T cell signaling from initial events to downstream responses was investigated, focusing on various aspects of T cell activation, including Ca microdomains, global Ca responses, NFAT-1 translocation, cytokine expression, and proliferation. While Ca microdomain formation was significantly reduced in the first milliseconds to seconds in CD8 T cells lacking P2X4 and P2X7 channels, global Ca responses over minutes were comparable between wild-type (WT) and knockout cells. However, the onset velocity was reduced in P2X4-deficient cells, and P2X4, as well as P2X7-deficient cells, exhibited a delayed response to reach a certain level of free cytosolic Ca concentration ([Ca]). NFAT-1 translocation, a crucial transcription factor in T cell activation, was also impaired in CD8 T cells lacking P2X4 and P2X7. In addition, the expression of IFN-γ, a major pro-inflammatory cytokine produced by activated CD8 T cells, and Nur77, a negative regulator of T cell activation, was significantly reduced 18h post-stimulation in the knockout cells. In line, the proliferation of T cells after 3 days was also impaired in the absence of P2X4 and P2X7 channels. In summary, the study demonstrates that purinergic signaling through P2X4 and P2X7 enhances initial Ca events during CD8 T cell activation and plays a crucial role in regulating downstream responses, including NFAT-1 translocation, cytokine expression, and proliferation on multiple timescales. These findings suggest that targeting purinergic signaling pathways may offer potential therapeutic interventions.
Zubiaur M, Terron-Camero L, Gordillo-Gonzalez F, Andres-Leon E, Barroso-Del Jesus A, Canet-Antequera L Front Immunol. 2025; 16:1441981.
PMID: 39995666 PMC: 11847871. DOI: 10.3389/fimmu.2025.1441981.